Mcl-1: A gateway to TRAIL sensitization

被引：97

作者：

Kim, Seok-Hyun

Ricci, M. Stacey

Ei-Deiry, Wafik S.

机构：

[1] Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Inst Translat Med & Therapeut,Dept Med Hematol On, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Inst Translat Med & Therapeut,Dept Genet, Philadelphia, PA 19104 USA

[3] Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Inst Translat Med & Therapeut,Dept Pharmacol, Philadelphia, PA 19104 USA

[4] Univ Penn, Sch Med, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA

来源：

CANCER RESEARCH | 2008年 / 68卷 / 07期

关键词：

D O I：

10.1158/0008-5472.CAN-07-6278

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The proapoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is being evaluated presently as a selective anticancer agent, but its limited effects against cancer cell lines has raised some concerns about its ultimate clinical utility. Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration-approved cancer drug. Using the TRAIL-sorafenib combination as a tactic to more effectively kill cancer cells may provide an effective tool to attack a variety of human cancers that are largely presently untreatable.

引用

页码：2062 / 2064

页数：3

共 18 条

[1] The Bcl-2 apoptotic switch in cancer development and therapy [J].

Adams, J. M. ;

Cory, S. .

ONCOGENE, 2007, 26 (09) :1324-1337

[2] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[3] Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis [J].

Han, J ;

Goldstein, LA ;

Gastman, BR ;

Rabinowich, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (15) :10153-10163

[4] Comparing antibody and small-molecule therapies for cancer [J].

Imai, Kohzoh ;

Takaoka, Akinori .

NATURE REVIEWS CANCER, 2006, 6 (09) :714-727

[5] Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia [J].

Konopleva, Marina ;

Contractor, Rooha ;

Tsao, Twee ;

Samudio, Ismael ;

Ruvalo, Peter P. ;

Kitada, Shinichi ;

Deng, Xingming ;

Zhai, Dayong ;

Shi, Yue-Xi ;

Sneed, Thomas ;

Verhaegen, Monique ;

Soengas, Maria ;

Ruvolo, Vivian R. ;

McQueen, Teresa ;

Schober, Wendy D. ;

Watt, Julie C. ;

Jiffar, Tilahun ;

Ling, Xiaoyang ;

Marini, Frank C. ;

Harris, David ;

Dietrich, Martin ;

Estrov, Zeev ;

McCubrey, James ;

May, W. Stratford ;

Reed, John C. ;

Andreeff, Michael .

CANCER CELL, 2006, 10 (05) :375-388

[6] Apo2L/TRAIL and its death and decoy receptors [J].

LeBlanc, HN ;

Ashkenazi, A .

CELL DEATH AND DIFFERENTIATION, 2003, 10 (01) :66-75

[7] Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells [J].

Liu, J. ;

Kumar, K. G. Suresh ;

Yu, D. ;

Molton, S. A. ;

McMahon, M. ;

Herlyn, M. ;

Thomas-Tikhonenko, A. ;

Fuchs, S. Y. .

ONCOGENE, 2007, 26 (13) :1954-1958

[8] MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization [J].

Meng, Xue Wei ;

Lee, Sun-Hee ;

Dai, Haiming ;

Loegering, David ;

Yu, Chunrong ;

Flatten, Karen ;

Schneider, Paula ;

Dai, Nga T. ;

Kumar, Shaji K. ;

Smith, B. Douglas ;

Karp, Judith E. ;

Adjei, Alex A. ;

Kaufmann, Scott H. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (41) :29831-29846

[9] mir-29 regulates Mcl-1 protein expression and apoptosis [J].

Mott, J. L. ;

Kobayashi, S. ;

Bronk, S. F. ;

Gores, G. J. .

ONCOGENE, 2007, 26 (42) :6133-6140

[10] Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation [J].

Rahmani, M ;

Davis, EM ;

Bauer, C ;

Dent, P ;

Grant, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (42) :35217-35227

← 1 2 →